SCHEMBL4043719

SCHEMBL4043719

COC(=O)c1cnc(N)c(C#N)c1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 3/20 0.49
KDM4E B2RXH2 4/20 0.49
ALDH1A1 P00352 3/20 0.49
MAPT P10636 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
RXFP1 Q9HBX9 1/20 0.49
PDGFRB P09619 1/20 0.45
KDR P35968 1/20 0.45
HPGD P15428 2/20 0.44
HSD17B10 Q99714 1/20 0.43
MAPK1 P28482 2/20 0.42
ATM Q13315 1/20 0.42
GAA P10253 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
XDH P47989 2/20 0.40
POLQ O75417 1/20 0.40
PSMD14 O00487 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6118870 0.83 MAPK1 (0.44) CSF1RKDM4EALDH1A1MAPTSMN1; SMN2
SCHEMBL15582692 0.83 GAA (0.49) CSF1RKDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL31132686 0.81 GAA (0.55) CSF1RKDM4EALDH1A1MAPTSMN1; SMN2
SCHEMBL31133019 0.81 GAA (0.55) CSF1RKDM4EALDH1A1MAPTSMN1; SMN2
SCHEMBL29877970 0.81 MAPK1 (0.42) CSF1RKDM4EALDH1A1MAPTSMN1; SMN2
SCHEMBL30908249 0.81 TDP1 (0.44) KDM4EALDH1A1MAPTSMN1; SMN2RXFP1
SCHEMBL2129547 0.81 TDP1 (0.44) KDM4EALDH1A1MAPTSMN1; SMN2RXFP1
SCHEMBL1960139 0.81 CSF1R (0.52) CSF1RKDM4EALDH1A1MAPTPDGFRB
SCHEMBL8326803 0.80 CYP4A11 (0.45) CSF1RKDM4EALDH1A1MAPTSMN1; SMN2
SCHEMBL31705858 0.78 KDM4E (0.51) CSF1RKDM4EALDH1A1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1268443-B1 2-HYDROXY-MUTILIN CARBAMATE DERIVATIVES FOR ANTIBACTERIAL USE SMITHKLINE BEECHAM PLC (GB) 2009-07-29 EP disclosed
US-6972297-B2 2-Hydroxy-mutilin carbamate derivatives for antibacterial use SMITHKLINE BEECHAM P.L.C. (GB) 2005-12-06 US disclosed
US-20030114674-A1 2-Hydroxy-mutilin carbamate derivatives for antibacterial use SMITHKLINE BEECHAM P.L.C. (GB) 2003-06-19 US disclosed
EP-1268443-A1 2-HYDROXY-MUTILIN CARBAMATE DERIVATIVES FOR ANTIBACTERIAL USE SmithKline Beecham p.l.c. (GB) 2003-01-02 EP disclosed
WO-2001074788-A1 2-HYDROXY-MUTILIN CARBAMATE DERIVATIVES FOR ANTIBACTERIAL USE SMITHKLINE BEECHAM PLC (GB) 2001-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030114674-A1 2-Hydroxy-mutilin carbamate derivatives for antibacterial use MSH6, MSH2, PMS2 CSF1R 1140/4885KDM4E 1084/4885ALDH1A1 1967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.